4-(3-Hexyl-2-imidazolon-1-yl)benzenesulphonyl chloride | 173901-10-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(3-Hexyl-2-imidazolon-1-yl)benzenesulphonyl chloride
• 英文别名: 4-(3-Hexyl-2-imidazolon-1-yl)phenylsulphonyl chloride；4-(3-hexyl-2-oxoimidazol-1-yl)benzenesulfonyl chloride
• CAS: 173901-10-5
• 化学式: C₁₅H₁₉ClN₂O₃S
• 分子量: 342.846
• InChiKey: XJCGPGZLRHVVSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  66.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-Hexyl-2-imidazolon-1-yl)benzenesulphonyl chloride 在 吡啶 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 4-(3-Hexyl-2-oxo-2,3-dihydro-imidazol-1-yl)-N-{4-[2-(2-hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenyl}-benzenesulfonamide
  参考文献：
  名称：

  Human β3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides

  摘要：

  Human beta(3) adrenergic receptor agonists containing 5-membered ring ureas were shown to be potent partial agonists with excellent selectivity over beta(1) and beta(2) binding. L-760,087 (4a) and L-764,646 (5a) (beta(3) EC50 = 18 and 14 nM, respectively) stimulate lipolysis in rhesus monkeys (ED50 = 0.2 and 0.1 mg/kg, respectively) with minimal effects on heart rate. Oral absorption in dogs is improved over other urea analogs. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00073-6
• 作为产物：
  描述：

  4-(氯磺酰)异氰酸苯酯 、 N-(2,2-dimethoxyethyl)hexan-1-amine 在 三氟乙酸 作用下， 生成 4-(3-Hexyl-2-imidazolon-1-yl)benzenesulphonyl chloride
  参考文献：
  名称：

  Human β3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides

  摘要：

  Human beta(3) adrenergic receptor agonists containing 5-membered ring ureas were shown to be potent partial agonists with excellent selectivity over beta(1) and beta(2) binding. L-760,087 (4a) and L-764,646 (5a) (beta(3) EC50 = 18 and 14 nM, respectively) stimulate lipolysis in rhesus monkeys (ED50 = 0.2 and 0.1 mg/kg, respectively) with minimal effects on heart rate. Oral absorption in dogs is improved over other urea analogs. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00073-6

文献信息

• Substituted sulfonamides as selective .beta..sub.3 agonists for the
  申请人：Merck & Co., Inc.

  公开号：US05541197A1

  公开（公告）日：1996-07-30

  Substituted sulfonamides are selective .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.

  替代磺酰胺是选择性β3肾上腺素受体激动剂，与β1和β2肾上腺素受体活性非常低，因此这些化合物能够增加细胞内的脂肪分解和能量消耗。因此，这些化合物在治疗2型糖尿病和肥胖症方面具有强大的活性。这些化合物还可以用于降低甘油三酯水平和胆固醇水平，或提高高密度脂蛋白水平或减少肠道蠕动。此外，这些化合物可以用于减少神经源性炎症或作为抗抑郁剂。这些化合物是通过将氨基烷基苯磺酰胺与适当取代的环氧化合物偶联而制备的。还揭示了在治疗糖尿病和肥胖症以及降低甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或增加肠道蠕动方面使用这些化合物的组合物和方法。
• US5541197A
  申请人：——

  公开号：US5541197A

  公开（公告）日：1996-07-30
• US5561142A
  申请人：——

  公开号：US5561142A

  公开（公告）日：1996-10-01